David is a partner and focuses on investments in novel therapeutics, often those that are near to first in human clinical testing.
Since joining Atlas Venture in 2010, David co-founded and served as chief executive officer of Arteaus Therapeutics, LLC which was acquired by Eli Lilly in 2014, as well as co-founder and CEO of Annovation Biopharma Inc. which was acquired by The Medicines Company in early 2015. He is currently a co-founder and acting CEO of Ataxion, founding board member of Delinia, co-founder of Quartet Medicine, and co-founder and executive chairman of Surface Oncology. David joined Atlas as Managing Director of Atlas Venture Development Corp. (AVDC), to lead our innovative, “built-to-buy” asset-centric initiative that partners with pharma and biotech companies to develop preclinical and clinical stage programs through to key value inflection points.
Previously, David was a member of the executive team at Infinity Pharmaceuticals (NASDAQ: INFI) and was responsible for all clinical research activities as the head of clinical development and medical affairs, as well as co-chairing the company’s scientific leadership team. In addition, as a member of the executive team, he shared responsibility for the creation and implementation of the overall corporate and business strategy that included going public in 2006, and establishing major corporate alliances with J&J, Amgen, Novartis, Medimmune/AZ and Purdue Pharma.
David obtained his MD from Harvard Medical School and completed his internship and residency training in internal medicine at Massachusetts General Hospital. Prior to his medical training, he was a curriculum director at Stanford University Medical Center, where he created Stanford’s first case-based medical ethics curriculum. He received a BA with honors from Stanford University. David serves on the board of Acera: The Massachusetts School for Science, Creativity, and Leadership, a STEM focused K-8 school, which he and his wife Courtney started in 2009.